Hereditary Breast and Ovarian Cancer Syndrome
"Hereditary Breast and Ovarian Cancer Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Autosomal dominant HEREDITARY CANCER SYNDROME in which a mutation most often in either BRCA1 or BRCA2 is associated with a significantly increased risk for breast and ovarian cancers.
| Descriptor ID |
D061325
|
| MeSH Number(s) |
C04.588.180.483 C04.588.322.455.431 C04.700.517 C13.351.500.056.630.705.431 C13.351.937.418.685.431 C16.320.700.517 C17.800.090.500.483 C19.344.410.431 C19.391.630.705.431
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hereditary Breast and Ovarian Cancer Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Hereditary Breast and Ovarian Cancer Syndrome".
This graph shows the total number of publications written about "Hereditary Breast and Ovarian Cancer Syndrome" by people in this website by year, and whether "Hereditary Breast and Ovarian Cancer Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hereditary Breast and Ovarian Cancer Syndrome" by people in Profiles.
-
Targeted sequencing for hereditary breast and ovarian cancer in BRCA1/2-negative families reveals complex genetic architecture and phenocopies. HGG Adv. 2024 Jul 18; 5(3):100306.
-
Prenatal genetic counseling practices regarding recommendations for cancer genetic counseling: A retrospective chart review from two academic institutions. J Genet Couns. 2022 10; 31(5):1062-1070.
-
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. Cancer. 2022 Jan 01; 128(1):94-102.
-
Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast J. 2019 07; 25(4):575-577.
-
Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy. Cancer. 2018 04 15; 124(8):1691-1700.
-
A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol. 2017 08; 146(2):399-404.
-
Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. Gynecol Oncol. 2017 08; 146(2):217-224.
-
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. J Natl Compr Canc Netw. 2017 01; 15(1):9-20.